Tvardi Therapeutics Reports Q3 2026 Net Loss of $6.1 Million

Tvardi Therapeutics reported a third-quarter 2026 net loss of $6.1 million, compared with $5.5 million a year earlier. Research and development expenses increased, while general and administrative expenses declined. The company ended September with $22.3 million in cash and cash equivalents and exp…